Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Combination Therapy With and Without Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Trials

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Sex Differences in the Achievement of Remission and Low Disease Activity in Rheumatoid Arthritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Growth and puberty in juvenile dermatomyositis: a longitudinal cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Dose-response relation between dietary sodium and blood pressure: a meta-regression analysis of 133 randomized controlled trials

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Development of Comorbidity in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  3. Impact of Diabetes on Risk of End Stage Renal Disease in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Vis graf over relationer

OBJECTIVE: The costs of biologic treatment per patient with rheumatoid arthritis (RA) are approximately 100 times the costs of treatment with a combination of conventional disease-modifying antirheumatic drugs (DMARDs). Despite this, biologic agents have not been proven superior. We compared the effects of combination DMARD therapies with and without biologic agents as therapy for patients with RA.

METHODS: Eight randomized controlled trials published in 10 articles were selected from a systematic literature search of 1,674 identified studies and integrated in a meta-analysis. These trials compared combinations of DMARDs versus a tumor necrosis factor (TNF) inhibitor plus methotrexate. Two reviewers independently entered data into standardized extraction forms. The combined effect measures were compared by means of the inverse variance method (continuous data) and the Mantel-Haenszel method (dichotomous data) using a random-effects model.

RESULTS: The primary outcome, radiographic progression score, did not differ between the combination DMARD group and the TNF inhibitor group, neither during the second year (-0.09 units [-0.61, 0.44]) of treatment or during the first 2 years (0.66 units [-0.12, 1.43]). There were significant differences in the radiographic progression score, the American College of Rheumatology criteria for 50% improvement (ACR50), and the ACR70 response criteria at 6 months in favor of TNF inhibitor treatment, but these differences were not present in patients treated with an initial steroid course and disappeared at 24 months, irrespective of the use of steroids.

CONCLUSION: The difference between DMARD combination treatments, including or excluding TNF inhibitors, is small. Due to the enormous cost differences, RA guidelines should recommend combination DMARD treatment before initiation of TNF inhibitors.

OriginalsprogEngelsk
TidsskriftArthritis Care & Research
Vol/bind67
Udgave nummer11
Sider (fra-til)1487-95
Antal sider9
ISSN2151-464X
DOI
StatusUdgivet - nov. 2015

ID: 46229016